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ABSTRACT Speciﬁc functional and pharmacological properties have recently been ascribed to G-protein-coupled receptor
(GPCR) dimers/oligomers. Because the association of two identical or two distinct GPCRmonomers seems to be required to elicit
receptor function, it is necessary to understand the exact nature of this interaction. We present here a novel method for de novo
protein design and its application to the prediction of mutations that can stabilize or destabilize a GPCR dimer while maintaining
the monomer’s native fold. To test the efﬁcacy of this new method, the dimer of the single-spanned transmembrane domain of
glycophorin A was used as a model system. Experimental data from mutagenesis of the helix-helix interface are compared with
computational predictions at that interface, and the model’s results are found to be consistent with the experimental ﬁndings. A
ﬂexible template was developed for the rhodopsin homodimer at atomic resolution and used to predict sets of three and ﬁve
mutations. The results are found to be consistent across eight case studies, with favoredmutations at each position. Mutation sets
predicted to be the most disruptive at the dimerization interface are found to be less speciﬁc to the ﬂexible template than sets
predicted to be less disruptive.
INTRODUCTION
Compelling evidence indicates that G-protein-coupled re-
ceptors (GPCRs) form multimeric complexes with distinct
pharmacological and functional properties (for recent review
articles, see (1–10)). Although most of this evidence comes
from in vitro experiments, recent studies using animal models
support a speciﬁc role for GPCR oligomerization in vivo and
in human pathologies. Accordingly, understanding the basis
of protein-protein interaction in GPCR oligomerization will
signiﬁcantly enhance our understanding of the molecular
mechanisms underlying GPCR cellular function, with the
promise of new and improved therapeutics targeting the
complex structures and their mechanisms.
Both computational and experimental efforts have been
made to identify the interface of GPCR oligomers, but the
speciﬁc molecular determinants required for stable protein-
protein interaction are still unknown. Rhodopsin is the only
GPCR whose native organization in rows of dimers has been
demonstrated directly using data from atomic force micros-
copy (11). Based on these data and the crystallographic
monomeric structure of rhodopsin (12), a three-dimensional
model of rhodopsin oligomers was proposed (13). Speciﬁ-
cally, this model consisted of intradimeric interfaces in-
volving transmembrane (TM) helices TM4 and TM5, and the
second intracellular loop, whereas helices TM1 and TM2 and
the third intracellular loop were involved in the formation of
rhodopsin dimer rows. Although it is possible that some
GPCRs use different oligomerization interfaces to achieve
functional selectivity, a systematic application of an en-
hanced correlated mutation-analysis-based approach (14,15)
to several rhodopsinlike GPCRs that are known to form
homo-oligomers identiﬁed TM1 and TM4 most often as
putative interfaces of dimerization/oligomerization. Cross-
linking studies of substituted cysteine residues in TM4 and
TM5 of rhodopsin (16), and in TM4 of dopamine D2 re-
ceptor, (17), further supported the involvement of these two
helices in the dimerization/oligomerization of GPCRs. The
recent demonstration that the putative dopamine D2 receptor
homodimerization interface involving TM4 is related to
function, and that activation of this receptor requires changes
at this interface (18), further justiﬁes the need for an im-
proved understanding of the exact nature of the interaction
between GPCR monomers. The ﬁnal goal is to suggest spe-
ciﬁc mutations that may affect the interaction between GPCR
monomers, and thereby either disrupt cross talk between
receptor subunits, or promote speciﬁc signaling cascades.
To this end, and to reduce the overwhelmingly large
number of mutagenesis and cross-linking experiments that
would otherwise be required to obtain the desired structural
insight, we developed a novel two-stage framework for com-
putational de novo protein design. The goal of this method is
to discover mutations that would stabilize or destabilize the
interfaces of a GPCR dimer while maintaining the mono-
mer’s native fold to the maximum extent possible. To test the
efﬁcacy of this new method, we used the dimer of the single-
spanned transmembrane domain of Glycophorin A as a
model system, and compared the predictions to experimental
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data from mutagenesis studies (19–21). The protein design
framework was then applied to the TM4,5-TM4,5 dimer of
the prototypic GPCR rhodopsin, and used to predict sets of
three and ﬁve simultaneous lipid-exposed mutations that are
likely to disrupt the dimerization interface of rhodopsin with
minimal changes in the structural integrity of the monomers.
THEORY
Novel two-stage framework for de novo
protein design
The framework for de novo protein design applied to the investigation of the
dimerization/oligomerization interface of rhodopsin involves two main
stages. The methodology is outlined in Fig. 1. The ﬁrst stage of the method,
termed the ‘‘sequence selection’’ stage, begins with a high-resolution ﬂex-
ible template and uses a distance-dependent force ﬁeld to select a rank-
ordered list of amino acid sequences that are predicted to be of low energy in
that template. As indicated in Fig. 1, these sequences are the input to the
second stage, the ‘‘fold validation’’ stage, in which sequences are selected
from a list of sequence positions that were rank-ordered by a criterion of
relative level of speciﬁcity for the ﬂexible template. This fold validation stage
is outlined in Fig. 2.
Deﬁning the ﬂexible template
The starting point for any de novo protein design method is the deﬁnition of
the template or backbone structure. The template is the de novo design
method’s representation of the desired three-dimensional structure, and
therefore appropriate deﬁnition is critical. Early methods of de novo protein
design assumed a rigid template, with the coordinates of all atoms ﬁxed in
space. This assumption was highly convenient because it signiﬁcantly re-
duces the complexity of the problem (22). However, it has been observed that
this unrealistic constraint renders some problems in de novo protein design
untreatable without the use of ﬂexible templates (23–25).
Methods have been created to incorporate template ﬂexibility; two of the
most popular are modeling atoms with smaller-than-natural atomic radii and
considering a discrete set of templates and sampling among the results (26).
Modeling atoms with smaller atomic radii, with typical reductions between 5
and 10%, allows steric overlapping of atoms due to backbone movements.
However, this approach has a number of disadvantages including an over-
estimation of attractive forces between atoms and the possibility of over-
packing atoms, particularly in the hydrophobic cores of target molecules
(27). Considering a discrete set of templates and sampling among the results
alleviates these disadvantages and allows for ﬂexibility to be incorporated
through the variations within the sets. Additionally, ﬂexibility can be con-
trolled across different regions of the protein. However, the various templates
must somehow be combined into a meaningful three-dimensional structure,
and the design problem must be solved for each template considered. This
greatly increases the complexity and computational difﬁculty of the problem.
There are several recent reviews of advances in de novo protein design (28–
30).
Here, we apply two strategies to incorporate ﬂexibility into the template.
Perhaps the most elegant way to incorporate backbone ﬂexibility is to allow
variability within the template itself. Following the method of Klepeis and
Floudas (26,31–33), we allow for backbone ﬂexibility by incorporating a
distance-dependent force ﬁeld in the sequence selection stage. First, we
represent the protein as a matrix of distances between a-carbons. Then, the
force ﬁeld considers pairwise interactions between residues as strictly dis-
tance-dependent, allowing rotational and torsional ﬂexibility. Distances be-
tween residues are discretized into a set of bins rather than scoring their
energy-continuous function. The bin sizes vary between 0.5 and 1 A˚, im-
plicitly allowing backbone movements of similar magnitude. It is important
to note that, because of the precision required by this method, a high-reso-
lution structure must be used as a starting point.
In addition, when multiple structural models are available, such as the
multiple NMR models of the glycophorin A dimer (34), a probability-
weighted-average method is used to increase template ﬂexibility by incor-
porating information from all models (26,27,33).
Developing a ﬂexible template for the
rhodopsin dimer
No high-resolution structure of the rhodopsin dimer is yet available. An
atomic-level resolution model of a rhodopsin dimer with TM4 and TM5 at
the dimerization interface was recently proposed (Protein Data Bank (PDB)
identiﬁcation code 1N3M) that uses atomic force microscopy data (13) and
the crystallographic structure of rhodopsin (12). We have recently described
the ﬁrst 45-ns molecular dynamics simulations of this model in an equili-
brated unit cell of hydrated palmitoyloleoyl phosphatidylcholine (35). The
resulting energy-optimized average structure of the converged interval of
these simulations (the last 17.5 ns of the 45-ns simulation) was used to de-
velop a ﬂexible template for the rhodopsin dimer using the strategy outlined
in the section above.
FIGURE 1 Overview of the de novo protein design method. The ﬁrst
stage of the method, the ‘‘sequence selection’’ stage, begins with a high-
resolution ﬂexible template and uses a distance-dependent force ﬁeld to
select a rank-ordered list of amino acid sequences that are predicted to be of
low energy in that template. Fig. 1 shows that these sequences are the input
to the second stage, the ‘‘fold validation’’ stage, in which sequences are
selected from the rank-ordered list of sequence positions that were found to
have the highest level of speciﬁcity for the ﬂexible template. This fold
validation stage is outlined in detail in Fig. 2.
Mutations Affecting GPCR Oligomerization 2471
Biophysical Journal 94(7) 2470–2481
Developing mutation sets
Once a ﬂexible template is deﬁned, an appropriate mutation set is developed.
The mutation set dictates which positions are considered for mutation and
which residues are allowed in each position. As illustrated in Fig. 1, this
selection is inﬂuenced by experimental results and the solvent-accessible
surface area (SASA). In the general case, all 20 amino acids can be con-
sidered at all n positions, and the total combinatorial complexity of the
problem is 20n. However, reducing the search space can be advantageous
both to reduce computer time and to increase biological relevance. For ex-
ample, when redesigning a protein with a particular binding region or cata-
lytically active domain, successful designs often focus on the surrounding
regions. Indeed, this was the case for compstatin, a synthetic peptide inhibitor
of complement 3, whose activity was increased 45-fold by redesigning res-
idues surrounding the binding loop (31,32,36–39).
Another simple and highly useful method for reducing the search space is
to consider only subsets of residues at each position. A popular classiﬁcation
of this kind is to separate the residues based on their environment. This
makes sense from a biochemical perspective for a number of reasons. Protein
cores are typically composed of tight packings of hydrophobic, nonpolar
amino acids. The surface of globular proteins is typically exposed to water,
and, accordingly, residues at the surface are generally hydrophilic, polar
amino acids. This idea has been used successfully by Harbury and co-
workers in their design of a-helical bundle proteins with a right-handed
superhelical twist (40), and, recently, by Hecht and co-workers to design a
four-helix bundle with a novel fold (41). We introduce this idea in residue
selection for our protocol, using the calculated SASA to classify residues
into three categories: surface (SASA. 50%), intermediate (20%, SASA,
50%), and core (SASA , 20%). SASA is readily calculated with the
program NACCESS (42). In the general case, only hydrophilic residues
(GNQHKRDESTP) are considered at surface positions, only hydrophobic
residues (AVILMFYW) are considered at core positions, and all 20 amino
acids except cysteine are considered at intermediate positions. Cysteine is
excluded from the mutation sets because of its ability to cross-link. However,
these guidelines can be modiﬁed; for example, it may be advantageous to
alter the mutation set at a given position if the native residue does not fall into
the category predicted by its SASA.
Implementing these approaches, we developed an appropriate mutation
set at the dimerization interface of rhodopsin by selecting the following ﬁve
positions as candidates for mutation: 4.41, 4.48, 4.55, 5.37, and 5.41. We
chose these speciﬁc positions in TM4 and TM5 because they correspond to
the closest symmetric interactions (distance between Cb atoms,11 A˚) at the
intradimeric interface of rhodopsin, as derived from atomic force microscopy
data (13). These positions are identiﬁed by the ‘‘generic numbering system’’
adopted for GPCRs to refer, comparatively, to structurally cognate receptors
(43). Brieﬂy, in this generic numbering scheme, two numbers (N1 and N2)
are assigned to amino acid residues in TMs. N1 refers to the TM number,
whereas the N2 numbering is relative to the most conserved residue in each
TM, which is assigned a value of 50. The other residues in the TM are
numbered in relation to this conserved residue, with numbers decreasing
toward the N-terminus and increasing toward the C-terminus.
Based on the SASA of native residues in the model (data not shown), two
sets of residues were used for the chosen positions of mutations: 1), all
residues except cysteine at the helix boundary positions 4.41 and 5.37; and
2), hydrophobic residues plus serine and threonine (AVILMFYWST) at
positions 4.48, 4.55, and 5.41. Cysteine was excluded from the mutation sets
because previous data show that mutations of lipid-exposed residues to
cysteine may cause GPCR cross-linking (16,17), and serine and threonine
were added to the standard hydrophobic set because of their prevalence on
the lipid-facing surface of membrane proteins.
Energy function
The energy function used in this work is a modiﬁed version of the high-
resolution (HR) force ﬁeld developed recently by Rajgaria et al. (44). The HR
force ﬁeld is a knowledge-based Ca-Ca distance-dependent potential that has
been shown to be highly effective in discriminating native protein folds from
highly similar sets of decoy structures at high resolution (root mean-square
deviation (RMSDs), 3 A˚), and medium resolution (3 A˚. RMSD. 10A˚)
(44). The HR force ﬁeld contains eight distance bins and considers a contact
to be any interaction where the Ca-Ca distance is ,9 A˚. It is the next gen-
eration version of the LKF force ﬁeld used previously in this method (45). To
better model the interactions across the dimerization interface of rhodopsin, a
longer-range version of the HR force ﬁeld was generated and designated the
HR-12 force ﬁeld. The HR-12 force ﬁeld contains 12 bins, and includes inter-
actions between residues with Ca-Ca distances up to 13 A˚. The HR-12 force
ﬁeld performs similarly to the HR force ﬁeld on all test cases (data not shown).
The energy measured by this type of HR force ﬁeld is a distance-de-
pendent approximation of the Gibbs free energy, since it is derived from
energy-minimized native conformations in the PDB. Additionally, this type
of force ﬁeld is advantageous for de novo protein design because evaluation
of contact energies requires only a table lookup. Hence it is very efﬁcient,
allowing for rapid evaluation of many candidate sequences.
The ﬂexible template and mutation set are used to design sets of residues
to ﬁt the template structure. Sequence selection is guided by the distance-
dependent force ﬁeld in a mixed integer linear programming model. In the
general case, residues are selected to minimize the energy of the structure
within the template; the novel sequences generated are designed to be spe-
ciﬁc to that template. However, to disrupt the dimerization process, we focus
on interactions across the dimerization interface and instead maximize the
energy, disrupting interactions between the monomer units.
Sequence selection
The sequence selection formulation used in this work is based on the original
formulation by Klepeis et al. (31,32). This model was recently improved by
FIGURE 2 Overview of the method for fold validation.
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Fung et al. and proven to be totally equivalent to, but computationally more
efﬁcient than, the original model (26,27,33). The integer linear programming
model then takes the form
min
y
j
i
;ylk
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n
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Consider set i¼ 1, . . . ,n to deﬁne the residue positions along the template
where n represents the total number of residues. At each position i, the set of
mutations is represented by j if g¼ 1, . . . ,mi, where, for the general case where
all mutations are allowed, mi ¼ 20"i. The equivalent sets k[ i and l[ j are
deﬁned so that pairwise interactions can be represented, and k. i is required
to ensure that all pairwise interactions are unique. Binary variables yji and y
l
k
are introduced to indicate the possible mutations at a given position. That is,
when a particular amino acid (j or l) is active at a given position (i or k),
variable yji or y
l
k indicate this by taking the value of 1. To ensure that there is
exactly one type of amino acid at each position, composition constraints
require the sum ofyji be equal to 1 for all positions i. Additionally, there are
two sets of RLT constraints that are introduced to reduce the integrality gap.
The model minimizes the energy function Ejlik over the entire structure. It is
important to note that the energy value then depends on the distance between
the a-carbons at the two backbone positions, i and j, as well as the type of
amino acids, k and l, at those positions. It should be noted that the binary
variables wjlik can be relaxed into continuous variables as shown by Zhu (46).
To predict sets of mutations that disrupt the dimerization interface of rho-
dopsin, the objective function is maximized rather than minimized. Accord-
ingly, residues of the highest energy are selected at the dimerization interface.
Increased ﬂexibility and ﬁdelity with multiple
structural models
When multiple structural models are available, such as the multiple NMR
models of the glycophorin A dimer, a probability-weighted-average method
is used to incorporate information from all models (26,27,33). Because of
protein ﬂexibility, the Ca-Ca distances across multiple structural models can
differ; for a particular pair of residues, they often span a number of bins. This
distribution of distances between residues is reﬂective of the residues’ con-
formational freedom. We therefore represent the pairwise energy contribu-
tion of each pair of residues as a sum of the contributions from all distances
spanned, weighted by the probability of ﬁnding the residues at each distance.
This energy contribution of the objective function is then written
min
y
j
i
;y
l
k
+
n
i¼1
+
mi
j¼1
+
n
k¼i11
+
mk
l¼1
+
b
d¼1E
jl
ik3Vðxi; xk; dÞ3wjlik;
where d is the current distance bin, b represents the total number of distance
bins in the force ﬁeld, andV is the weight given to that bin for the current pair
of residues, deﬁned as the fraction of structures in which the distance
between residues xi and xk falls into bin d. This method increases the
ﬂexibility of the template by spanningmultiple distances for each interaction.
At the same time, the ﬁdelity of the model is increased because the
probability-weighted distribution is more representative of the interaction
between two residues than any single distance can be.
To illustrate this method, imagine a protein for which 20 structural models
are available. In these models, the distance between residues a and b falls
into bin 2 eight times, bin 3 ten times, and bin 4 two times. The values of V
for these bins are then 0.4, 0.5, and 0.1, respectively. If the distance-
dependent force ﬁeld Ejlik has the values 6.0, 4.0, and 2.0 units, respec-
tively, for the interaction between a and b over these bins, then the total
contribution of the interaction between these residues would be 4.6 units.
Development of structure-based constraints
The mixed-integer linear programming model allows for straightforward
incorporation of constraints to increase the biological relevance of the results.
As seen in Fig. 1, experimental results and homology information are in-
corporated in this step, resulting in speciﬁcally targeted constraints. For
example, charge can be maintained over the entire protein, within speciﬁc
domains of the protein, or both. The number of simultaneous mutations can
be limited, allowing a small number of mutations with maximal effect to be
introduced across a large search space. Also, the composition of the protein
or a region of the protein can be controlled by imposing minimum and
maximum quantities of speciﬁc amino acids or groups of amino acids within
the design. For example, the number of hydrophobic amino acids in existing
b-strands can be bounded to enhance the formation of b-sheets.
Incorporation of knowledge-based weights
We incorporated three distinct sets of knowledge-based weights in the rho-
dopsin runs to illustrate how such knowledge-based information can be in-
cluded in the new type of de novo protein design method we present here.
Such information can be very useful in improving the speciﬁcity of the re-
sults. As outlined in Fig. 1, these weights allow knowledge from homology
studies to be incorporated into the energy function, supplementing the energy
function with structural data focused on the region, or even position, of in-
terest. Incorporation into the energy function is straightforward; the objective
function is multiplied by two additional terms l
j
i3l
l
k. The term l
j
i represents
the weight of amino acid j at position i in the protein backbone, and llk rep-
resents the same information for the second residue being considered in the
pairwise energy function. Note that for positions not selected for mutation,
the weight factors l are given the value of 1. This prevents bias of some
interactions over others based on weight assigned to native residues in non-
mutated positions.
One set of knowledge-based input comes from two scales previously
described for membrane proteins: the structure surface fraction (SF) scale,
and the rhodopsin surface propensity (RhoSP) scale (47). These scales de-
scribe what types of residues one might expect to ﬁnd on the surface of
general membrane proteins (SF) and of rhodopsinlike proteins (RhoSP).
They are based on the inside/outside-facing distribution of the residues on the
template obtained from a bioinformatics procedure described in detail (47).
The procedure yields an amino acid property scale (APS) that corresponds to
the propensity of residues to be located on the lipid-oriented TM surface in
membrane protein. The knowledge-based scale was shown to reﬁne pre-
dictions based on conservation criteria alone (47). The APS-based prediction
method is available on the web-accessible server ProperTM http://icb.med.
cornell.edu/crt/ProperTM/ProperTM.xml.
To increase further the speciﬁcity of the structure-based information
content, we also developed a position-dependent set of knowledge-based
weights for class A GPCRs. These weights represent the probability of
ﬁnding a residue at a given position across all class A GPCRs. An archive of
GPCR sequence information was obtained from the GPCRDB (48) and a
database of human class A GPCRs was built from these sequences. In total,
there were 545 receptors used. Human receptors were selected to minimize
bias for receptors heavily studied across species. Multiple pairwise align-
ments were then performed using CLUSTAL W 1.83 (49). Taking bovine
rhodopsin as a ‘‘gold standard’’ for class A GPCRs, each helix of each re-
ceptor was aligned with the corresponding helix in bovine rhodopsin. The
probability of each residue occurring at each position was then calculated.
Note that a residue was tallied only if it was found aligned with one of the
residues in bovine rhodopsin; residues aligning with gaps were not tallied.
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The resulting weights for the positions mutated in this study are presented in
Table 1. Full data for all positions are available in Supplementary Materials,
Tables S1–S7).
Method for fold validation
As outlined by the sequence of procedural steps shown in Fig. 1, once a rank-
ordered list of sequences has been selected into the template by the sequence
selection stage, the sequences are further validated by a second stage, de-
signed to predict the sequence’s speciﬁcity for the ﬂexible template. In the
general case, the same template is used for both stages, and the second stage
provides reﬁnement of the results from sequence selection. However, to
disrupt the dimerization of rhodopsin, the sequence selection stage maxi-
mizes the energy rather than minimizing it. Here, we use the crystal structure
of the rhodopsin monomer in the second stage, and the resulting predictions
are for sets of mutations that will destabilize the dimerization process of
rhodopsin while remaining speciﬁc to the native fold of the monomer.
In the two-stage framework developed by Klepeis et al. (31,32), the
second stage uses ab initio structure prediction techniques based on the aBB
deterministic global optimization solver with an objective function of a full-
atomistic force ﬁeld over the set of independent dihedral angles that describe
the conﬁguration of the system (50–64). However, these computations are
not currently feasible for proteins the size of rhodopsin. Here, we present an
alternative method for fold speciﬁcity; this method is outlined in Fig. 2.
Brieﬂy, a conformation ensemble is generated by simulated annealing using
the CYANA 2.1 package (65,66). The resulting hundreds of structures are
subjected to local energy minimizations using TINKER (67) with the AM-
BER force ﬁeld (68). The ensembles of structures from candidate sequences
are then statistically compared to yield a template speciﬁcity factor, STemp.
Details of this procedure are reported below.
First, upper and lower bounds on both the distances between a carbons
and the f and c angles between residues are extracted from the ﬂexible
template. When only one structural model is available, these bounds are
deﬁned parametrically, with distances of610% and angles of625.We note
that true backbone ﬂexibility is incorporated into this method. The para-
metrically deﬁned template allows for any possible values of Ca-Ca dis-
tances and dihedral angles.
Then, for both the sequence of interest and the native sequence, an en-
semble of random structures (conformers) is generated within the conﬁnes of
the ﬂexible template. This is done using the CYANA 2.1 software package
for NMR structure reﬁnement (65,66). CYANA 2.1 performs annealing
calculations that simulate a rapid heating of the protein followed by a slow
cooling in which high-temperature torsion dynamics and annealing torsion
dynamics are performed. Violations of van derWaals radii and of the ﬂexible
template are minimized, thereby minimizing the energy of the target struc-
tures. Hundreds of these structures are generated within the conﬁnes of the
ﬂexible template; for this work we have generated 500 conformers for each
sequence. For each conformer in the ensemble, local minimizations are then
performed with the TINKER (67) package using the BFGS quasi-Newton
optimization algorithm, as guided by gradients in the fully atomistic force
ﬁeld AMBER (68). AMBER is then used to evaluate the potential energy of
the ﬁnal conformer structure. The use of TINKER, AMBER, and CYANA is
widespread and documented in the literature, even though there have been
reports (69) discussing the inaccuracies of the parameters used within
AMBER and suggesting improvements.
To analyze the results, a method similar to that used by Klepeis et al.
(31,32) for ensemble comparison in fold validation was employed. First, the
mean and standard deviation of both RMSD and AMBER energies were
found for the native sequence. Upper bounds on both RMSD and energy
were then established; for RMSD, the upper bound was selected as 1.5
standard deviations above the mean, in the energy the upper bound was
selected as 2 standard deviations from the mean. A structure is considered to
make a contribution to the ensemble only if its energy and RMSD both fall
under these upper bounds. This is illustrated in Fig. 3.
The speciﬁcity of each mutant sequence to the target template is then
calculated relative to the native sequence using a Boltzmann distribution.
Both the predicted energy of each conformer and its RMSD from the tem-
plate structure are used in this calculation.
We deﬁne the ‘‘set native’’ as the set of all data points from the native se-
quence that are below both upper bounds, and ‘‘set novel’’ as the set of all data
points from the novel sequence that meet the same criterion. The template
speciﬁcity factor, STemp, is then calculated using Boltzmann probabilities:
STemp ¼
+
i2novelexp½bEi
+
i2nativeexp½bEi
; where b ¼ 1
kBT
:
The approximate criterion described here does not claim to be a rigorous
calculation of stability or free energy. However, AMBER is designed to
quantify the potential energy of a protein in a given three-dimensional
conformation, and it provides a good approximation of the enthalpy of the
protein when folded into the template. Combined with the large sampling of
conformational space around the template, approximating an entropy cal-
culation, the template speciﬁcity factor approximates the speciﬁcity of the
fold within the conﬁnes of the ﬂexible template.
In summary, the proposed approach consists of two stages. In the ﬁrst
stage, the sequence selection model minimizes the free energy, which is
approximated as a distance-dependent force ﬁeld derived from existing
structures in the PDB. In the second stage, we perform a fold-speciﬁcity
calculation via two protein-folding calculations, one around the ﬂexible
template and the other without template restrictions. Then, based on the
ensembles of the generated conformers we rerank the predicted sequences
based on the fold speciﬁcity. As a result, in stage 1, we aim for better stability,
whereas in stage 2 we aim for better speciﬁcity, and the proposed approach
combines the two in a unique way. This is similar to the ‘‘design-in/design-
out’’ method described by Koehl and Levitt (70,71).
RESULTS AND DISCUSSION
Glycophorin A: a model system
To test the efﬁcacy of the new method, we compare our re-
sults with the experimental data from the Fleming group on
the dimerization of glycophorin A (19–21). Their recent studies
have probed the relationship between structure, sequence,
and stability of the dimerization of glycophorin A, a human
erythrocyte protein with a single transmembrane domain
TABLE 1 Class A GPCR position-speciﬁc weights
No. Res A V I L F M Y W C G P T S Q N H K R E D
4.41 H 8.2 7.8 0.9 6.7 2.6 2.2 1.7 1.5 3.2 3.3 3.9 5.8 5.6 5.0 4.6 6.7 8.0 20.2 0.9 1.3
4.48 F 14.5 20.6 11.9 24.0 8.1 5.2 0.8 0.2 4.0 4.4 — 3.6 2.6 — — — — 0.2 — —
4.55 A 13.3 14.5 8.0 30.1 5.1 3.5 1.2 — 1.2 8.6 1.0 5.3 6.6 0.4 1.2 — — 0.2 — —
5.37 S 11.1 8.5 10.9 7.2 1.2 1.9 1.9 1.7 0.6 6.0 3.1 5.8 6.4 4.7 3.5 1.7 3.1 2.1 16.7 2.1
5.41 Y 8.1 6.6 7.5 11.1 27.5 2.8 12.6 1.9 3.2 3.2 0.4 6.4 4.9 0.8 0.6 0.6 0.2 0.8 1.1 0.2
Each value represents the weight of the residue (column) at a speciﬁc position (row). Values in bold represent the native residue for bovine rhodopsin at each
position. Res, residue.
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containing a GxxxG motif that is known to form symmetric
homodimers. The structure was solved with NMR and the
coordinates for 20 models are deposited in the PDB ﬁle
1AFO. This information was used to construct the ﬂexible
template as described in Methods, and both stages of calcu-
lations (see Fig. 1, Stage I, to yield rankings and energies, and
Stage II to yield Stemp values) were performed as described in
Methods on all reported mutations.
Three case studies had been performed experimentally
(19–21), examining three types of mutations. We repeat the
studies in silico and compare our results to those found ex-
perimentally. We note that the calculations in the two-stage
approach presented here relate to the experimentally deter-
mined DDG of mutation, but they are not the same. The se-
quence selection stage minimizes the distance-dependent force
ﬁeld (44) in selection of mutations and the second stage pro-
vides a metric for structural speciﬁcity. As a result, our ap-
proach does not explicitly calculateDDG for the dimer, but our
results are consistent with those determined experimentally.
Single alanine mutations
In a ﬁrst study, single alanine mutations were made along the
75–87 helix fragment of glycophorin A, including both
‘‘lipid-facing’’ residues (77, 78, 81, 85, and 86) with side
chains pointing away from the dimerization interface, and
‘‘helix-facing’’ residues (75, 76, 79, 80, 83, 84, and 87) with
side chains pointing into the interface (20). In these experi-
ments, the lipid-facing alanine mutations were found to cause
no statistically signiﬁcant change in the energy of dimeriza-
tion, with the exception of a moderate stabilizing effect in
mutation I85A. In stark contrast with the lipid-facing resi-
dues, the helix-facing alanine mutations were found to have
moderate to strong destabilizing effects, especially mutation
G83A in the GxxxG motif (residues 79–83).
The results from computational studies of these mutants
are presented in Tables 2 and 3. In the sequence selection, we
ﬁnd a strong stabilizing effect from mutation I85A. We also
note a moderate stabilizing effect of mutation G86A, which
does not contradict the experimental results. Whereas the
sequence-selection phase fails to identify the stabilizing ef-
fect of the GxxxG motif, we ﬁnd all other mutations desta-
bilizing, in strong accord with the experimental results.
Additionally, in the speciﬁcity calculations, we also ﬁnd that
all alanine mutations, including those that disrupt the GxxxG
motif, produce monomers that are less speciﬁc to the template
structure than the wild-type sequence.
A number of factors may explain the failure of the se-
quence-selection phase to identify the GxxxG motif as sta-
bilizing. It has been shown that this complex motif is not
required for the dimerization of the glycophorin A trans-
membrane domain, and that its presence is not sufﬁcient for
dimerization (21). Although the function of the glycines in
this motif is still not fully understood, proposed mechanisms
suggest that they may permit long-range interactions by al-
lowing tighter helical packing. (19,72). Furthermore, where
GxxxG motifs occur in the context of the membrane, they
may facilitate packing of helical conformations distinct from
those seen in soluble proteins (73). Therefore, we propose
that the role of these glycines may be different from that
played by any glycine used to derive the HR-12 force ﬁeld. It
is also possible that the Ca-Ca distance-dependent approxi-
mation used in the sequence selection phase is not sufﬁcient
to model this distinct type of packing.
Single aliphatic mutations along the helix-facing residues
A second study carried out in Fleming’s lab (21) explored
the requirement of the GxxxG motif (residues 79–83) for
FIGURE 3 Illustration of upper bounds on RMSD and AMBER energy.
Thick lines indicate the upper bounds. Data points in shaded regions are not
considered in further calculations.
TABLE 2 Single alanine mutations along the dimerization interface of glycophorin A: lipid-facing residues
Stage 1 rank Stage 1 energy Stage 2 STemp 77 ILE 78 PHE 81 MET 85 ILE 86 GLY
3 733 1.0 ILE PHE MET ILE GLY
6 663 0.9 ALA PHE MET ILE GLY
1 809 0.9 ILE PHE MET ALA GLY
5 685 0.9 ILE PHE ALA ILE GLY
2 775 0.8 ILE PHE MET ILE ALA
4 693 0.8 ILE ALA MET ILE GLY
Each sequence is listed in one row, and the wild-type sequence is identiﬁed in the header. Stage 1 energy is in arbitrary units, determined by the distance
dependent force ﬁeld. Higher speciﬁcity factor STemp is better; by deﬁnition the native sequence has STemp¼1. Mutated residues are in bold. Wild-type
residues at each location are shown in the table header along with the position number.
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glycophorin A dimerization using a series of single mutations
of the ‘‘helix-facing’’ residues to large aliphatic residues and
to glycines. This study also repeats mutations to alanine;
however, these are discussed in the previous section and are
therefore not repeated. The experiments again ﬁnd that the
GxxxG motif stabilizes the dimer but is not required for di-
merization (Fig. 4). As noted previously, our method does not
identify the GxxxG motif to be stabilizing in the sequence-
selection phase, and therefore mutations that alter these
glycines are almost all found to stabilize the dimerization
interface. Accordingly, the results segregate those that dis-
rupt the glycines in the GxxxG motif (Table 4) from those
that do not (Table 5).
Experimentally, all but two point mutations along the he-
lix-facing residues were found to be destabilizing. Mutation
V80L was found to be moderately stabilizing, and mutation
I76V was found to have no effect on the energy of dimer-
ization. We ﬁnd mutation V80L as the best stabilizing mu-
tation in the sequence-selection phase (Rank 1, Energy763
in Table 5) and in the speciﬁcity calculations we ﬁnd it more
speciﬁc to the template (STemp ¼ 1.1) than the wild-type se-
quence (STemp ¼ 1.0). Also, we ﬁnd mutation I76V to be
highly speciﬁc to the template. Mutations I76G and I76L are
also found to be speciﬁc to the template.
Scanning double alanine mutations
In a third experimental study on glycophorin A (19), alanine
scan double mutations were performed along the dimeriza-
tion interface to further probe residue interactions. All double
mutants that did not disrupt the glycines in the GxxxG motif
were found to be destabilizing in these experiments, and the
results were found to be more complex than could be pre-
dicted from coupling single mutations. In agreement with
these results, we found that all but one mutant were moder-
ately to signiﬁcantly less speciﬁc to the template than wild-
type receptor (see Tables 6 and 7, Stage 2 STemp). The sole
exception to this trend was the double leucine mutant
G79LG83L, in which both glycines in the GxxxG motif had
been replaced by leucines. Despite the agreement of our
second-stage results with experimental data, our method
failed to recognize the GxxxG motif as stabilizing. In fact,
mutations disrupting both glycines were found to be stabi-
lizing relative to wild-type, as seen by their lower Stage
1 energies.
In the experiments, it was noted that mutations tend not to
be additive in their ability to disrupt the dimerization, with a
few notable exceptions. In particular, mutation 75A87A was
found not to dimerize. Along with a destabilizing result from
the sequence selection stage, we ﬁnd the sequence extremely
nonspeciﬁc to the template, the least speciﬁc among all
mutations tested. This is evidenced by the increase in energy
relative to the wild-type sequence (Table 6, Stage1 Energy)
and the extremely low STemp value of 0.4 (Table 6, Stage2
STemp). This is in full agreement with the lack of dimerization
found in the experiments.
TABLE 3 Single alanine mutations along the dimerization interface of glycophorin A: helix-facing residues
Stage 1 rank Stage 1 energy Stage 2 STemp 75 LEU 76 ILE 79 GLY 80 VAL 83 GLY 84 VAL 87 THR
3 733 1.0 LEU ILE GLY VAL GLY VAL THR
6 679 0.9 LEU ALA GLY VAL GLY VAL THR
1 822 0.8 LEU ILE ALA VAL GLY VAL THR
2 814 0.8 LEU ILE GLY VAL ALA VAL THR
8 667 0.8 LEU ILE GLY ALA GLY VAL THR
7 677 0.7 LEU ILE GLY VAL GLY ALA THR
4 723 0.7 ALA ILE GLY VAL GLY VAL THR
5 695 0.7 LEU ILE GLY VAL GLY VAL ALA
Each sequence is listed in one row, and the wild-type sequence is identiﬁed in the header. Stage 1 energy is in arbitrary units, determined by the distance-
dependent force ﬁeld. Higher-speciﬁcity factor STemp is better; by deﬁnition, the native sequence has STemp¼1. Mutated residues are in bold. Wild-type
residues at each location are shown in the table header along with the position number.
FIGURE 4 Experimentally determined energies of dimerization for single
aliphatic mutations. Reprinted from Doura et al. (21).
TABLE 4 Single aliphatic mutations that disrupt the glycines in
the GxxxG motif of glycophorin A
Stage 1 rank Stage 1 energy Stage 2 STemp 79 GLY 83 GLY
5 857 1.3 THR GLY
7 843 1.3 GLY THR
3 896 1.2 GLY LEU
1 933 1.1 LEU GLY
4 879 1.1 VAL GLY
8 843 1.1 GLY VAL
11 733 1.0 GLY GLY
9 781 0.9 SER GLY
10 778 0.9 GLY SER
6 855 0.8 GLY ILE
2 898 0.8 ILE GLY
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Dimerization-disrupting mutations of rhodopsin
Generation of the dimer template
Analysis of our results from nanosecond-timescale molecular
dynamics simulations (35) of a 1N3M-like intradimeric ar-
rangement of rhodopsin (11,13) revealed a more compact
complex structure than had previously been suggested for
the rhodopsin dimer (6,13,74). The average structure of the
equilibrated portion of these simulations (last 17.5 ns of the
45 ns) was used as a starting point for our novel de novo
protein design method.
Selection of positions and mutation sets
As described in the Methods section, the positions investi-
gated for the mutation sets are 4.41, 4.48, 4.55, 5.37, and
5.41. All residues except cysteine are considered for the helix
boundary positions 4.41 and 5.37, whereas hydrophobic
residues plus serine and threonine (AVILMFYWST) are
considered for positions 4.48, 4.55, and 5.41. Additionally,
these positions carry a net positive charge due to the histidine
at position 4.41. Therefore, we impose a charge constraint,
requiring that the mutations maintain the net charge of 11.
Because hydrophilic residues are only allowed at two posi-
tions, this constraint enforces that exactly one of them carries
a positive charge in each solution.
Incorporation of knowledge-based weights
The key criterion of the knowledge-based information in-
corporated in the application is the probability of ﬁnding a
particular residue on the outward (lipid)-facing side of the
TM helix, rather than on its inward (into the protein bundle)-
facing side. This probability has been assessed and quantiﬁed
from structural data available for membrane proteins (47).
The information implicit in the weights from the structure SF
method (see (47)) includes the residue distribution between
the surface and the interior of membrane proteins, calibrated
for the speciﬁed regions in the TMs (i.e., the intra- and ex-
tracellular parts and the central regions). The RhoSP weights
come from an alternative method described in parallel (47),
where the crystal structure of bovine rhodopsin and an
alignment of 328 rhodopsinlike GPCRs considered to share
its structure were used to determine the inside/outside dis-
tribution of residues. For each of these criteria, the informa-
tion obtained from the analysis served to develop an APS that
corresponds to the propensity of residues to be located on the
TM surface. The weights represent these scales of propen-
sities, as detailed in Table 8.
Use of the class A GPCR position-speciﬁc weights provide
interesting information regarding the ﬁve positions studied
here. As expected by their prevalence on the surface of
membrane proteins, we see a moderate amount of serine and
threonine at all positions. Positively charged residues domi-
nate at position 4.41, providing further support for our en-
forcement of a positive charge at the interface. Large aliphatic
TABLE 5 Single aliphatic mutations that do not disrupt the
glycines in the GxxxG motif of glycophorin A
Stage 1
rank
Stage 1
energy
Stage 2
STemp 75 LEU 76 ILE 80 VAL 84 VAL 87 THR
4 747 1.4 LEU LEU VAL VAL THR
12 719 1.3 LEU VAL VAL VAL THR
16 570 1.1 LEU GLY VAL VAL THR
2 754 1.1 LEU ILE VAL LEU THR
1 763 1.1 LEU ILE LEU VAL THR
11 725 1.0 VAL ILE VAL VAL THR
8 733 1.0 LEU ILE VAL VAL THR
7 736 0.9 LEU ILE VAL VAL VAL
15 594 0.9 LEU ILE GLY VAL THR
3 750 0.9 LEU ILE VAL VAL LEU
14 629 0.8 GLY ILE VAL VAL THR
6 738 0.8 ILE ILE VAL VAL THR
9 733 0.8 LEU ILE ILE VAL THR
10 728 0.8 LEU ILE VAL ILE THR
13 681 0.7 LEU ILE VAL VAL SER
5 742 0.7 LEU ILE VAL VAL ILE
Each sequence is listed in one row, and the wild-type sequence is identiﬁed
in the column heading. Stage 1 energy is in arbitrary units, determined by
the distance-dependent force ﬁeld. Higher-speciﬁcity factor STemp is better;
by deﬁnition, the native sequence has STemp¼1. Mutated residues are in
bold. Wild-type residues at each location are shown in the table header
along with the position number.
TABLE 6 Double alanine mutations that do not disrupt the glycines in the GxxxG motif of glycophorin A
Stage 1 rank Stage 1 energy Stage 2 STemp 75 LEU 76 ILE 79 GLY 80 VAL 83 GLY 84 VAL 87 THR
WT 1 733 1.0 LEU ILE GLY VAL GLY VAL THR
76A80A 9 637 0.8 LEU ALA GLY ALA GLY VAL THR
75A76A 3 672 0.7 ALA ALA GLY VAL GLY VAL THR
76A84A 11 623 0.7 LEU ALA GLY VAL GLY ALA THR
75A84A 4 667 0.6 ALA ILE GLY VAL GLY ALA THR
75A80A 5 663 0.6 ALA ILE GLY ALA GLY VAL THR
76A87A 7 641 0.6 LEU ALA GLY VAL GLY VAL ALA
80A84A 8 639 0.6 LEU ILE GLY ALA GLY ALA THR
80A87A 10 629 0.5 LEU ILE GLY ALA GLY VAL ALA
84A87A 6 660 0.5 LEU ILE GLY VAL GLY ALA ALA
75A87A 2 685 0.4 ALA ILE GLY VAL GLY VAL ALA
Each sequence is listed in one row, and the wild-type sequence is given in the column heading and highlighted in the table. Stage 1 energy is in arbitrary
units, determined by the distance-dependent force ﬁeld. Higher-speciﬁcity factor STemp is better; by deﬁnition, the native sequence has STemp ¼ 1. Mutated
residues are in bold. Wild-type residues at each location are shown in the column headings, along with the position number.
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residues dominate at positions 4.48, 4.55, and 5.37. We also
note the occurrence of some large hydrophilic residues at
5.37, but we believe that this is due to this position’s prox-
imity to the surface of the membrane, which may be slightly
different across individual receptors. Aromatic residues are
most common at position 5.41, but in keeping the interme-
diate SASA at this position there is some prevalence of all
types of residues.
Analysis of the results
We present eight case studies in total. First, setting an upper
limit of three simultaneous mutations, sequences are selected
as 1), ‘‘unweighted’’ (without the use of any knowledge-
based weights); 2), using the class A GPCR position-speciﬁc
weights; 3), using the SF scale; and 4), using the RhoSP
scale. We then repeat these four case studies, allowing up to
ﬁve simultaneous mutations in each sequence.
To disrupt the dimerization interface of rhodopsin, the
objective function during the sequence selection phase corre-
sponds to the maximization of the energy of the distance-
dependent force ﬁeld. At the same time, we also seek to
maintain the structure of the monomer as close as possible to
the native fold. Based on initial results from the speciﬁcity
calculations, we were concerned that total energy maximiza-
tion would produce sequences that do not fold speciﬁcally into
the target structure. Therefore, we generate a rank-ordered list
of 2,000 sequences for each case and perform the second stage
of calculations on solutions 1–40 (the ‘‘most disrupted set’’)
and 1961–2000 (the ‘‘least disrupted set’’). As predicted, the
template speciﬁcity factor STemp was much higher in general
for the least disrupted set, and only a few solutions from the
most disrupted set met the arbitrary minimum value for the
template speciﬁcity factor STemp deﬁned in Methods.
The sequence selection calculations were solved using the
GAMS modeling language coupled to the CPLEX linear
programming solver on an Intel Pentium-4 3.2 GHz work-
station. Generation of 2,000 solutions required an average of
6 h. A Beowulf cluster containing 80 nodes of dual 3.0 GHz
Intel Xeon processors was used to serially perform the second
stage of calculations, and ;36 h of processor time was re-
quired for each sequence.
Table 9 presents an illustrative set of results, taken from the
case study using the class A GPCR position-speciﬁc weights
and allowing up to three mutations. We show all results
meeting the arbitrary cutoff. We note that in this case study,
none of the solutions from the predicted least disrupted set is
found to be highly speciﬁc to the template structure, with no
solution meeting the minimum STemp value of 5 (maximum
value is 1.2: compare to other results below with double- and
triple-digit values). This suggests that the GPCR position-
speciﬁc weights provide key structural information, enhancing
the method’s ability to ﬁnd solutions that are structurally
destabilizing.
Table 10 presents a summary of the results across all case
studies for three mutations. The solutions are all found to be
highly speciﬁc to the template as measured by the large STemp
TABLE 7 Double alanine mutations disrupting the glycines in the GxxxG motif of glycophorin A
Stage 1 rank Stage 1 energy Stage 2 STemp 75 LEU 76 ILE 79 GLY 80 VAL 83 GLY 84 VAL 87 THR
79L83L 1 918 1.5 LEU ILE LEU VAL LEU VAL THR
WT 13 733 1.0 LEU ILE GLY VAL GLY VAL THR
76A79A 8 764 0.9 LEU ALA ALA VAL GLY VAL THR
79A83A 2 914 0.8 LEU ILE ALA VAL ALA VAL THR
76A83A 10 760 0.8 LEU ALA GLY VAL ALA VAL THR
79A84A 7 764 0.7 LEU ILE ALA VAL GLY ALA THR
80A83A 12 748 0.7 LEU ILE GLY ALA ALA VAL THR
75A79A 3 816 0.6 ALA ILE ALA VAL GLY VAL THR
75A83A 4 805 0.6 ALA ILE GLY VAL ALA VAL THR
79A87A 5 784 0.6 LEU ILE ALA VAL GLY VAL ALA
83A87A 6 777 0.6 LEU ILE GLY VAL ALA VAL ALA
83A84A 9 761 0.6 LEU ILE GLY VAL ALA ALA THR
79A80A 11 756 0.6 LEU ILE ALA ALA GLY VAL THR
Mutated residues are in bold.
TABLE 8 Surface fractions and the rhodopsin SP scale (47)
Residue Structure SF Rhodopsin SP scale
A 36 58
C 39 38
D 29 0
E 31 8
F 50 99
G 25 61
H 20 32
I 54 100
K 55 57
L 57 98
M 44 50
N 35 1
P 36 70
Q 33 47
R 39 47
S 27 40
T 37 58
V 53 92
W 60 77
Y 47 84
Note that the scales have been normalized to 100 for easier comparison.
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values. The complete results from all the studies are available
in Supplementary Material.
We ﬁnd a number of general trends across all case studies
for three mutations, as summarized in Tables 10 and 11. The
histidine at position 4.41 is always mutated. Additionally,
there is a trend to shift the positive charge away from this
position to position 5.37, natively occupied by a serine. In the
sequences with the highest speciﬁcity, this position tends to
be mutated to arginine, although in some solutions with good
speciﬁcity it is mutated to lysine as well. Also, position 4.55
is the least mutated; when the wild-type alanine is mutated, it
is usually to a serine.
Not surprisingly, when up to ﬁve mutations are allowed,
we ﬁnd much more diversity and complexity of solutions, in
particular at positions 4.41 and 5.41. However, clear trends
are evident. First, there is a near-complete shift of the positive
charge from histidine 4.41 to an arginine at position 5.37.
This is consistent with the prevalence of this shift in the case
studies (above) allowing up to three mutations. Second, we
note that serine now dominates at position 4.55, replacing the
wild-type alanine residue that was most common in the three-
mutation cases. Finally, phenylalanine 4.48 is mutated in
each case to tryptophan, tyrosine, or serine.
It is interesting to note that alanine is selected in a number
of cases as an amino acid to disrupt the dimerization. Yet in
almost all cases, it occurs in a solution from the solution
range 1961–2000, indicating that although an alanine muta-
tion may not promote the largest local disruption, it may
provide a compromise between disruptions of the dimer and
fold speciﬁcity. This trend occurs across case studies with
both three and ﬁve mutations.
SUPPLEMENTARY MATERIAL
To view all of the supplemental ﬁles associated with this
article, visit www.biophysj.org.
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TABLE 10 A compilation of dimerization-disrupting solutions
across the three-mutation case studies of rhodopsin
Source STemp 4.41 HIS 4.48 PHE 4.55 ALA 5.37 SER 5.41 TYR
UNW 272 GLN PHE SER ARG TYR
UNW 57 ALA TRP ALA ARG TYR
UNW* 29 ARG SER SER SER TYR
UNW 381 THR PHE SER ARG TYR
UNW 35 SER PHE ALA LYS SER
GPCRA 120 TYR TRP ALA ARG TYR
GPCRA 109 PHE PHE ALA ARG ALA
GPCRA 127 ILE TYR ALA ARG TYR
GPCRA 70 ARG PHE ALA GLY THR
GPCRA 49 TYR PHE ALA ARG TRP
SF 118 ALA THR ALA ARG TYR
SF* 19 ARG TRP ALA SER ALA
SF* 18 ARG ALA ALA SER SER
SF 8 PHE PHE ALA LYS THR
SF 59 ARG TYR ALA GLN TYR
RHO_SP 206 ASN PHE SER ARG TYR
RHO_SP 190 GLY PHE ALA ARG THR
RHO_SP* 23 ARG SER ALA SER SER
RHO_SP 28 ARG PHE SER SER VAL
RHO_SP 22 ARG PHE SER SER TYR
A group of solutions were selected for their high speciﬁcity to the template
and for their heterogeneity. UNW, unweighted; GPCRA, class A GPCR
position-speciﬁc weights; SF, surface-fraction scale; RHO_SP, rhodopsin
SP scale. Mutated residues are in bold.
*Denotes a solution from the ‘‘most disrupted set’’.
TABLE 9 Illustrative set of results from a case study
STemp 4.41 HIS 4.48 PHE 4.55 ALA 5.37 SER 5.41 TYR
127 ILE TYR ALA ARG TYR
120 TYR TRP ALA ARG TYR
109 PHE PHE ALA ARG ALA
70 ARG PHE ALA GLY THR
49 TYR PHE ALA ARG TRP
25 ARG TYR ALA SER TYR
14 ARG PHE SER SER ILE
13 ALA PHE SER LYS TYR
8 GLY PHE ALA LYS TRP
5 TYR PHE ALA LYS MET
Column entries are the complete results meeting the arbitrary cutoff on
STemp from the case study using the class A GPCR position-speciﬁc
weights, where up to three mutations are allowed. Note that all sequences
are from solutions 1961–2000. Each row represents one sequence. Mutated
residues are in bold. The native residues are shown in the column headings.
TABLE 11 A compilation of dimerization-disrupting solutions
across the ﬁve-mutation case studies of rhodopsin
Source STemp 4.41 HIS 4.48 PHE 4.55 ALA 5.37 SER 5.41 TYR
UNW 403 GLN TRP SER ARG SER
UNW* 233 GLY SER SER ARG SER
UNW 151 ALA ALA SER ARG VAL
UNW* 133 GLY SER SER ARG ALA
UNW* 72 ARG SER SER GLY THR
UNW* 246 ARG SER SER ASN THR
UNW 132 TYR SER SER ARG VAL
UNW 121 ALA SER THR ARG ALA
GPCRA 224 GLN TYR TYR ARG TRP
GPCRA 192 PHE SER SER ARG THR
GPCRA* 155 GLY TRP SER ARG TRP
GPCRA* 145 GLY TYR SER ARG TRP
GPCRA* 107 GLY SER SER ARG TRP
SF* 151 GLN TRP TRP ARG TRP
SF* 122 ASN TRP TRP ARG TRP
SF 95 ALA SER ALA ARG MET
SF 92 PRO THR TRP ARG SER
SF 78 ALA ALA SER ARG TRP
RHOSP 617 ASN ALA ALA ARG ALA
RHOSP* 382 ASN SER SER ARG SER
RHOSP 343 ASN SER MET ARG THR
RHOSP 306 ASN MET THR ARG SER
RHOSP* 233 GLY SER SER ARG SER
A heterogeneous group of solutions were selected for their high speciﬁcity
to the template. UNW, unweighted; GPCRA, class A GPCR position-
speciﬁc weights; SF, surface-fraction scale; RHO_SP, rhodopsin SP scale.
Mutated residues are in bold.
*Denotes a solution from the ‘‘most disrupted set’’.
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